BioInvent International
LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV)
Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022. The change from Small Cap is a result of Nasdaq's annual review of the average market value in the Nordic market segments. The Mid-cap segment includes companies with a market capitalization between EUR 150 million and EUR 1 billion.
"The promotion of the BioInvent share to the Nasdaq Nordics Mid Cap segment further bolsters the profile of our company, and the significant progress we have made in expanding our pipeline with several candidates in clinical development," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander, Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/678565/BioInvent-Moves-to-NASDAQ-Stockholms-Mid-Cap-Segment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Corp. Files Year-End Financial Results17.9.2025 14:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / September 17, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Form 10-K with audited financial results for the fiscal year ended May 31, 2025. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Operational and Strategic Highlights for Fiscal Year 2025 Completed the acquisition of ALLCOT Group, expanding Karbon-X's global footprint and integrating world-class expertise. Launched trading operations, marking a critical milestone in validating the Company's business model and initiating its revenue-generating activities. Entered landmark partnerships with major energy producers and with the BK Dukes, reflecting strong market confidence in Karbon-X's vision and capabilities. Financial Highlights for Fiscal Year 2025 Revenue surged to $3.16 million, up from $0.41 million in the prior year, mark
TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers16.9.2025 20:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched two new global credentials for healthcare workers specializing in rehabilitation, habilitation, and restorative care. The Certified Global Health Worker-Rehabilitation (CGHW-R) and the Certified Global Health Worker-Rehabilitation Advanced (CGHW-RA) have been developed specifically for eligible health workers worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination. These credentials, along with the Certified Global Nurse-Rehabilitation (CGN-R) that TruMerit established last year, are intended to advance and improve services for the more than two billion people worldwide who need this care. The CGHW-RA credential was developed for those with a degree or diploma in a rehabilitation field. These include clinicians, educators, and instructors with physiotherapy, occup
Second Blue Magic Netherlands Event Set for November 1816.9.2025 18:30:00 CEST | Press release
Registration Site Is Open and Dutch Innovators Are Encouraged to Attend and Apply to Present Capabilities SAN DIEGO, CALIFORNIA / ACCESS Newswire / September 16, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI), in collaboration with the Dutch Ministry of Defence and the Dutch Ministry of Economic Affairs, will host its second Blue Magic Netherlands (BMNL) event on November 18, 2025. BMNL 2025 follows the successful first event in 2024 and will take place at the MELT at Avular building, a world-class venue for technology interchange near Brainport Eindhoven, the center of the Dutch high-technology manufacturing industry. The registration site can be accessed at www.ga-asi.com/blue-magic-netherlands-2025. "The first BMNL event was a huge success for Dutch industry," said Brad Lunn, managing director for GA-ASI. "We've built strong investment opportunities with Dutch companies - including Arceon, Emergent Swarm Solutions, and Saluqi Motors - and now we're looking to build on th
U.S. Polo Assn. Celebrates Sport and Style as Official Apparel Sponsor of the 2025 Engel & Völkers Berlin Maifeld Polo Cup16.9.2025 13:00:00 CEST | Press release
Sports Brand Supports Germany's High-Goal Polo Event for Sixth Consecutive Year BERLIN, GERMANY AND WEST PALM BEACH, FL / ACCESS Newswire / September 16, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly partnered as the Official Jersey and Apparel Sponsor of the Engel & Völkers Berlin Maifeld Polo Cup, also known as the German High-Goal Championship 2025, held August 22-31, 2025, in Berlin. This prestigious tournament is the pinnacle of the polo season in Germany and is one of the most celebrated events in European polo.Engel & Völkers Berlin Maifeld Polo Cup Winners Photo Credit: Guadalupe Aizaga The finals weekend for the Engel & Völkers Berlin Maifeld Polo Cup took place at the iconic Maifeld Stadium, the same historic venue where the sport of polo was last played in the 1936 Olympic Games. Qualifying matches were held August 21-28 at the Prussian Polo and Country Club, leading to a thrilling finale that showcased the very best
Case IQ Introduces Clairia: AI Assistant for Compliance, Workplace Investigations and Case Management16.9.2025 11:00:00 CEST | Press release
Transforming how ethics, compliance, and HR teams across Europe resolve cases with speed, intelligence and confidence. LONDON, GB / ACCESS Newswire / September 16, 2025 / Case IQ has announced the launch of Clairia, an AI assistant designed to simplify case management and provide clarity at every step. Clairia empowers European organizations, HR teams, and compliance officers to manage cases with efficiency, speed and confidence from the initial complaint or report to case resolution. Clairia is built into Case IQ's case management solution and is designed for ethics, compliance, HR, and investigations teams who require accuracy, consistency, and accountability. It delivers clear and context-aware suggestions on how to proceed that draw on uploaded documents such as internal codes of conduct and applicable regulatory frameworks like the EU Whistleblower Directive, and most recently in the UK, the new corporate criminal offence of "Failure to Prevent Fraud" under the Economic Crime and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom